The Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Novartis AG
NVS
Current price
$123.98
As a major Swiss pharmaceutical company with a significant US presence, Novartis could be a prime candidate for a similar move to close the valuation ...
As a major Swiss pharmaceutical company with a significant US presence, Novartis could be a prime candidate for a similar move to close the valuation gap with US peers.
Sanofi
SNY
Current price
$49.94
This French pharmaceutical giant could benefit from a valuation re-rating by shifting its primary listing to the US, where a large portion of its sale...
This French pharmaceutical giant could benefit from a valuation re-rating by shifting its primary listing to the US, where a large portion of its sales originate.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
These companies represent a significant valuation opportunity based on the growing trend of international pharmaceutical firms considering US listings. With the world's largest healthcare market and deepest capital pools, America offers these companies potentially higher valuations than their home exchanges.
What You Need to Know
This collection includes both potential movers to US exchanges and existing US-listed pharma companies that serve as valuation benchmarks. These research-driven firms develop and sell innovative medicines globally, with significant revenue already coming from the American market.
Why These Stocks
We've carefully selected companies that could benefit from this transatlantic listing trend. The portfolio includes European and international pharma giants that may be undervalued compared to their US counterparts, creating potential for substantial value unlocking if they follow AstraZeneca's path.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+213.55%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 213.55% over the next year.
Stocks Rated Buy by Analysts
11 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Valuation Gap Opportunity
These international pharma companies often trade at significant discounts to their US peers. If they follow AstraZeneca's lead, a US listing could quickly unlock substantial shareholder value.
Wall Street's Premium Effect
The US market typically assigns higher valuations to innovative pharmaceutical companies. This collection positions you ahead of a potential re-rating wave as more European firms seek these premium valuations.
First-Mover Advantage
AstraZeneca's potential move signals the start of a trend that industry insiders are watching closely. By investing now, you gain exposure before wider market attention drives valuations higher.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Consumer Caution: Value Prevails
A sharp drop in consumer sentiment, driven by persistent inflation fears, signals a potential shift in household spending. This theme focuses on companies poised to benefit as consumers prioritize essential goods and seek value.
Refining a New Opportunity: Venezuelan Crude Returns
Following a renewed U.S. license, Chevron has resumed oil shipments from Venezuela, creating a new supply of heavy crude for the market. This development presents a potential investment opportunity in U.S. refiners and logistics firms positioned to benefit from this strategic shift.
Consumer Strength: The Retail Rebound
A surprising surge in U.S. retail sales, driven by strong automotive and home furnishing purchases, signals continued consumer strength despite economic headwinds. This theme focuses on retailers and manufacturers in these key discretionary sectors that are benefiting from the robust consumer demand.
Frequently Asked Questions
Everything you need to know about the product and billing.